14108-81-7

Basic information

• Product Name: Glycine, N-(3,4-dichlorophenyl)-, ethyl ester
• CAS NO: 14108-81-7
• Molecular Formula: C10H11Cl2NO2
• Molecular Weight: 248.109
• Mol File: 14108-81-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Glycine, N-(3,4-dichlorophenyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-(3,4-dichlorophenyl)-, ethyl ester(14108-81-7)
• EPA Substance Registry System: Glycine, N-(3,4-dichlorophenyl)-, ethyl ester(14108-81-7)

Safety Data

• Hazardous Substances Data: 14108-81-7(Hazardous Substances Data)

Upstream product

• 75-34-3 1,1-dichloroethane 
• 65051-17-4 (3,4-Dichloroanilino)-acetic acid 
• 105-36-2 ethyl bromoacetate 
• 95-76-1 m,p-dichloroaniline 

Downstream Products

• 1003878-18-9 ethyl N-(3,4-dichlorophenyl)-N-methylglycinate 
• 1003878-20-3 ethyl 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetate 
• 1003878-59-8 ethyl N-(3,4-dichlorophenyl)-N-[2-(methyloxy)ethyl]glycinate 
• 65051-17-4 (3,4-Dichloroanilino)-acetic acid 
• 14108-53-3 2-(3,4-dichlorophenyl-1-ylamino)acethydroxamic acid 
• 1003878-21-4 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetic acid 
• 851680-18-7 (3,4-dichloro-phenylamino)-acetic acid hydrochloride 

Relevant articles and documents

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1β, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.

Novel acetamide derivatives containing 3,4-dichlorophenyl group or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases contain

The present invention relates to an acetamide derivative including a 3,4-dichlrophenyl group, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for

Development of potent and selective small-molecule human Urotensin-II antagonists

This work describes the development of potent and selective human Urotensin-II receptor antagonists starting from lead compound 1, (3,4-dichlorophenyl)methyl{2-oxo-2-[3-phenyl-2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl}amine. Several problems relating to oral bioavailability, cytochrome P450 inhibition, and off-target activity at the kappa opioid receptor and cardiac sodium channel were addressed during lead development. hUT binding affinity relative to compound 1 was improved by more than 40-fold in some analogs, and a structural modification was identified which significantly attenuated both off-target activities.